FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol

The FDA cleared a new class of cholesterol pill last week, and the approval is worth understanding carefully before the marketing machine gets ahead of the evidence.

On July 16, the agency approved Lipfendra (enlicitide), a once-daily tablet made by Merck, according to an announcement reviewed directly from the FDA press office. The drug is the first oral member of the PCSK9 inhibitor class, a group of therapies that had, until now, existed only as injections.

Here's what that means in plain terms. PCSK9 inhibitors work by blocking a protein that degrades LDL receptors on liver cells. Block the protein, keep the receptors, and the liver pulls more LDL cholesterol out of circulation. The injectable versions, evolocumab (Repatha) and alirocumab (Praluent), have been on the market for about a decade and come with robust cardiovascular outcomes data showing they reduce heart attacks and strokes. Lipfendra uses the same mechanism but is formulated as a novel macrocyclic peptide that can survive the gut, rather than a monoclonal antibody that can't.

The FDA's approval was built on two randomized, double-blind, placebo-controlled trials involving 3,207 adults with hypercholesterolemia, including patients with and without heterozygous familial hypercholesterolemia, all of whom were already on maximally tolerated statin therapy. In the first trial, which enrolled adults with established or high-risk atherosclerotic cardiovascular disease, Lipfendra cut LDL-C by an average of 56 percent at 24 weeks compared with placebo. Across both studies, reductions reached as high as 60 percent, matching the ballpark of the injectable PCSK9 agents, according to reporting in the American Journal of Managed Care.

The convenience argument is real. As Medical News Today reported in its coverage of the approval, the injectable PCSK9 drugs require self-injection every two to four weeks, or a twice-yearly clinic visit for inclisiran (Leqvio), and they need refrigerated storage. Lipfendra is a room-temperature pill taken daily. For patients who refuse injections, have needle phobia, or lack reliable cold-chain access, that's a meaningful difference.

But there's a gap clinicians should name out loud when they write that first prescription. Lipfendra doesn't yet have a dedicated cardiovascular outcomes trial showing it prevents heart attacks and strokes the way FOURIER and ODYSSEY OUTCOMES did for its injectable competitors. Similar benefits are anticipated based on mechanism and LDL reduction magnitude, and that's a reasonable scientific inference. It isn't the same as data. Patients and prescribers deserve to know the distinction.

The indication, per the FDA announcement, is adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise. It isn't a first-line monotherapy. The trials enrolled people already on maximally tolerated statins. Clinicians prescribing it outside that context would be going beyond the studied population.

Cardiovascular disease remains the leading cause of death in the United States, and elevated LDL is one of its most modifiable risk factors, as FDA's Michael Davis, M.D., Ph.D., noted in the agency's press statement. That framing is accurate. What it doesn't answer is how many of the roughly one in four U.S. adults with high LDL cholesterol, per American Heart Association estimates cited by NBC News, are the right candidates for this specific drug right now.

The answer, based on the trial design, is people who haven't reached LDL goals on statins alone and who either can't or won't do injections. That's a real population. It's not every person with a high cholesterol number on a routine lab panel.

Pricing hasn't been publicly announced as of this writing. Given where injectable PCSK9 inhibitors landed at launch, and how slowly payer access followed, access is the next story here. A pill that works beautifully in a trial but sits behind a prior authorization wall doesn't do much for the patient sitting in a primary care exam room.

Sources cited:
- FDA press announcement, July 16, 2026 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol)
- American Journal of Managed Care (AJMC) (https://www.ajmc.com/view/fda-approves-enlicitide-first-oral-pcsk9-for-high-cholesterol)
- Medical News Today (https://www.medicalnewstoday.com/articles/new-cholesterol-pill-lipfendra-gets-fda-approval-2-experts-weigh-in)
- NBC News (https://www.nbcnews.com/health/heart-health/fda-approves-new-kind-cholesterol-pill-rcna587798)
- GlobeNewswire (Merck press release) (https://www.globenewswire.com/news-release/2026/07/17/3329256/0/en/fda-approves-first-oral-pcsk9-inhibitor-to-lower-ldl-cholesterol-in-adults-with-high-cholesterol.html)